Siwei (Shanghai) Biotechnology Co., Ltd.

Clinical Trials

Registration Number Clinical Center Test Candidate Indication Objective of Study
ChiCTR1900023000 Shanghai East Hospital of Tongji University mRNA-based Personalized Cancer Vaccine Advanced Malignant Solid Tumors To explore the safety and efficacy of personalized cancer vaccine encoding neoantigen in the treatment of advanced malignant solid tumors.
NCT03468244 Shanghai Changhai Hospital mRNA-based Personalized Cancer Vaccine Gastric Adenocarcinoma To determine the safety, tolerability and cytokinetics and efficacy of the personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma.
NCT03908671 First Affiliated Hospital of Zhengzhou University mRNA-based Personalized Cancer Vaccine Esophageal Cancer, NSCLC To assess the safety and tolerability and efficacy of mRNA personalized tumor vaccines encoding neoantigen for unresectable or metastatic advanced esophageal and non-small cell lung cancers with standard treatment failure or no standard treatment.
About Us
- Our Story
- News Updates
- Contact Us
Platforms
- mRNA Synthesis Platform
- LPP Delivery Platform
- GMP Manufacturing
Pipeline
- Therapeutic Areas
- Development Candidates
Patients
- Clinical Trials
Partnering
- Investors
Join Us
- Opportunities